High-Dose Vitamin C IV Therapy: A Clinical Guide

Written by Empire Medical Training Editorial Team

Medically reviewed by Chris Croley, MD Board-Certified Anesthesiologist & Critical Care Physician; Empire Chief Medical Officer

Updated June 2026 ·11 min read

High-dose vitamin C IV therapy is one of the most misunderstood treatments in the wellness space — alternately oversold as a cancer cure and dismissed as a placebo drip. The truth is more interesting and more useful than either caricature. Vitamin C is the same molecule whether you swallow an orange or run 50 grams through a vein, but the dose and the route change what it does in the body so completely that high-dose IV vitamin C is, pharmacologically, a different therapy than the supplement in your cabinet.

This guide situates high-dose vitamin C within the broader field of IV nutrition therapy and is written for clinicians who want an accurate, honest overview. It is clinical education, not medical advice, and nothing here is a treatment recommendation, a protocol, or a substitute for individualized clinical judgment and current evidence.

What is high-dose vitamin C IV therapy?

Vitamin C, or ascorbic acid, is a water-soluble vitamin the body does not store, so it must be replenished regularly. Most people know it as a dietary antioxidant. What makes the intravenous form clinically distinct is a hard ceiling on oral absorption: as Dr. Chris Croley teaches in Empire’s IV course, the gut can absorb only about 3 to 4 grams of vitamin C per day. Push above that orally and you do not get more vitamin C in the blood — you get GI intolerance, diarrhea, and stomach cramping as the unabsorbed dose stays in the gut.

This is the genuine bioavailability rationale for the IV route, and it is the one place where the “IV gives 100% absorption” framing is not marketing — it is pharmacokinetics. By bypassing the digestive system entirely, an infusion can deliver tens of grams directly into the bloodstream and reach plasma concentrations that simply cannot be produced by any oral dose. That difference is the heart of the pharmacologic-versus-physiologic distinction: physiologic doses (the few grams the gut allows) keep vitamin C in its everyday role; pharmacologic doses (the 25–75 g range delivered IV) take it somewhere the diet never can.

So the right mental model is not “more of the same vitamin.” It is a dose-dependent change in what the molecule does — and understanding that switch is the whole point of the next section.

How it works: antioxidant at low levels, pro-oxidant at IV levels

At physiologic, everyday levels, vitamin C is a potent antioxidant. It neutralizes free radicals by donating electrons, reducing oxidative stress and protecting cells from damage. In Empire’s curriculum this is the low-dose lane: support for collagen synthesis (vitamin C is a required cofactor for the enzymes that cross-link collagen), immune support, and anti-inflammatory effects. These are real and relatively uncontroversial roles.

The mechanism that defines high-dose therapy is the opposite. Dr. Croley’s framing is precise: at the very large concentrations only achievable by IV, vitamin C “acts very differently in the body.” Rather than functioning as an antioxidant, it becomes a pro-oxidant — it drives the generation of hydrogen peroxide as a byproduct. The hypothesis behind oxidative therapy is that this hydrogen peroxide can selectively stress cells with weaker antioxidant defenses (such as some tumor cells) while leaving healthy cells relatively unharmed, because normal cells clear hydrogen peroxide more efficiently.

That same pro-oxidant chemistry is what makes high-dose vitamin C both interesting and risky. The hydrogen peroxide that is the proposed mechanism is also the reason a patient who cannot defend their red cells against oxidative stress can be harmed. You cannot separate the mechanism from the safety screen — they are the same biology viewed from two sides. The specific dose ranges, infusion rates, and how intent maps to protocol are taught in Empire’s IV Nutrition Therapies course; this page deliberately teaches the why, not the recipe.

Uses and claims — what high-dose vitamin C is actually for

Honesty matters most in this section, because high-dose vitamin C is where wellness marketing most often outruns the evidence. Here is the candid version.

Immune and inflammatory support. At high doses, vitamin C is used to support immune function — stimulating the production and activity of white blood cells such as neutrophils and lymphocytes — and to help reduce inflammation. It is also used for some chronic infections and as part of post-surgical or high-physical-stress recovery. These uses are plausible and widely offered, though the strength of evidence varies by indication.

Adjunctive oncology — read this carefully. The use that draws the most attention is in cancer supportive care, and it is the one most prone to dangerous overstatement. The honest framing is unambiguous: high-dose vitamin C is investigational and adjunctive only. It is not a cancer treatment, it does not cure cancer, and it must never be presented to a patient as a replacement for conventional oncology care. Where it is used, it is as a complement to chemotherapy or radiation — typically with the goal of supporting quality of life and possibly reducing treatment side effects — under the supervision of the patient’s oncology team, never instead of them. Any provider offering it must be able to draw that line clearly and document that the patient understands it.

Wellness and anti-aging. Lower-dose IV vitamin C is also marketed for general antioxidant support, skin and collagen health, and vitality. These are reasonable wellness applications at physiologic-style dosing, but they should be described as wellness — not as treatment for disease — and the FDA is explicit that providers cannot make health claims their therapies have not been proven to support.

What the evidence shows

The evidence picture is genuinely mixed, and saying so is the credible position. For the antioxidant, immune, collagen, and anti-inflammatory roles of lower-dose vitamin C, the biology is well established. For high-dose, pro-oxidant oncology use, the data are far less settled.

As covered in Empire’s course, mainstream medical organizations remain cautious because the clinical trials of high-dose vitamin C in cancer have shown mixed results, and the exact mechanism of any effect on tumors is still not fully understood. Critics make a fair point: without larger, more rigorous studies, high-dose vitamin C in cancer care should be approached with caution. There is also a specific theoretical concern that the antioxidant properties of vitamin C could, in principle, interfere with the oxidative stress that chemotherapy and radiation rely on to kill cancer cells — which is precisely why coordination with the treating oncologist is non-negotiable.

At the same time, many patients report meaningful improvements in quality of life and reduced severity of treatment side effects. That subjective benefit is real to those patients, but it is not the same as evidence that the therapy treats the underlying disease, and the two should never be conflated. The responsible summary: established roles at lower doses, promising-but-unproven roles at high doses, and an obligation to present that honestly.

The critical safety screen: G6PD, oxalate, and renal cautions

If you take one operational rule from this page, take this one. Dr. Croley underscores it twice in the course, and so will we: every patient must be screened for G6PD deficiency before receiving high-dose or oxidative vitamin C.

Why G6PD. Glucose-6-phosphate dehydrogenase is the enzyme red blood cells depend on to regenerate the antioxidant defenses that protect them from oxidative stress. High-dose vitamin C is, by design, a pro-oxidant that generates hydrogen peroxide. In a patient who is G6PD-deficient, those red cells cannot defend themselves, and the infusion can trigger acute hemolysis — destruction of red blood cells — a serious, potentially life-threatening reaction. This is not a rare-edge-case footnote; it is the single most important screen in high-dose vitamin C, and it is the same mechanism (hydrogen peroxide) that makes the therapy work in the first place.

Oxalate and kidney stones. Vitamin C is metabolized to oxalate, and high doses increase oxalate excretion. That raises the risk of kidney stones, particularly in patients with a history of renal stones or impaired kidney function. For this reason renal function must be assessed before high-dose infusions, and patients with significant renal impairment require real caution.

Conceptually, the pre-treatment workup includes labs such as a CBC and CMP, with G6PD specifically when high-dose or oxidative vitamin C is planned, and a review of kidney function where indicated. (Exact lab panels, thresholds, monitoring intervals, and how to respond to an adverse reaction are taught in the course.) The point for this page is simpler: high-dose vitamin C is a medical procedure with specific, screenable risks — and the screen is mandatory, not optional.

Who it suits

High-dose vitamin C is best suited to appropriately selected, medically supervised patients who have been screened for the specific risks above. In practice the strongest candidates are those with normal G6PD status and adequate renal function, who understand the realistic — and honestly framed — goals of the therapy.

• Good fit: patients seeking immune or recovery support who clear the safety screen; oncology patients using it as an adjunct, with their oncologist informed and involved; wellness-oriented patients at lower, antioxidant-range dosing.
• Caution or unsuitable: any patient who is G6PD-deficient or unscreened; patients with significant renal impairment or a history of oxalate kidney stones; and anyone who has been led to believe — or is being sold — that vitamin C will treat or replace conventional cancer therapy.

For patients whose primary goal is immune resilience rather than oxidative therapy, the lower-dose approach is often the more appropriate starting point; see our companion guide on IV therapy for immune support. As always, the right candidate is defined by a good-faith medical exam and individualized judgment, not by a marketing menu.

Training: offering high-dose vitamin C responsibly

Because high-dose vitamin C sits at the intersection of real pharmacology, real risk, and heavy marketing, competent training is what separates a responsible service from a liability. The clinical skill is not running a drip; it is knowing which dose for which intent, which patient to screen out, and how to talk honestly with a patient about what the therapy can and cannot do.

Empire Medical Training’s IV Nutrition Therapies course, developed and taught by Dr. Chris Croley, covers the antioxidant-versus-pro-oxidant pharmacology, the dose ranges and how they map to clinical intent, the mandatory G6PD and renal screening, patient selection and contraindications, monitoring, and the federal and state regulatory framework — including the prohibition on unsubstantiated claims. It situates high-dose vitamin C within the full IV toolkit so providers can add it to an aesthetic or wellness practice safely and compliantly.